Risk of deterioration in the creditworthiness of business partners and investment and financing counterparties
First written in FY2019. 5 of 7 entries say "Mitigated", first in FY2022. Latest entry: FY2026.
The whole theme swung hardest in 2023: 10 of 40 companies on the "Worse" side.
13 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「These loans include ¥19,337 million in loans to medical corporations and other partners in the medical services business, which is primarily operated by the consolidated subsidiary セコム医療システム株式会社, and a loan loss allowance of ¥7,838 million has been recorded against these loans.」
Loans to medical corporations and others decreased from ¥21,887 million in the previous fiscal year to ¥19,337 million, while the corresponding allowance for doubtful accounts decreased from ¥8,894 million to ¥7,838 million. - FY2025MitigatedAnnual report
「This includes loans of ¥21,887 million to affiliated medical corporations and others in the medical services business, against which an allowance for doubtful accounts of ¥8,894 million has been recorded.」
Loans to medical corporations and others decreased from ¥23,477 million in the previous fiscal year to ¥21,887 million, while the corresponding allowance for doubtful accounts decreased from ¥9,108 million to ¥8,894 million. - FY2024MitigatedAnnual report
「This includes loans of ¥23,477 million to affiliated medical corporations and others, against which an allowance for doubtful accounts of ¥9,108 million has been recorded.」
Loans to medical corporations and others decreased from ¥25,872 million in the previous fiscal year to ¥23,477 million, while the corresponding allowance for doubtful accounts decreased from ¥9,726 million to ¥9,108 million. - FY2023MitigatedAnnual report
「This includes loans of ¥25,872 million to affiliated medical corporations and others, against which an allowance for doubtful accounts of ¥9,726 million has been recorded.」
Loans to medical corporations and others decreased from ¥29,701 million in the previous fiscal year to ¥25,872 million, while the corresponding allowance for doubtful accounts decreased from ¥11,054 million to ¥9,726 million. - FY2022MitigatedAnnual report
「This includes loans of ¥29,701 million to affiliated medical corporations and others, against which an allowance for doubtful accounts of ¥11,054 million has been recorded.」
Loans to medical corporations and others decreased from ¥33,709 million in the previous fiscal year to ¥29,701 million, while the corresponding allowance for doubtful accounts decreased from ¥12,305 million to ¥11,054 million. - FY2021WorsenedAnnual report
「This includes loans of ¥33,709 million to affiliated medical corporations and others, against which an allowance for doubtful accounts of ¥12,305 million has been recorded.」
An allowance for doubtful accounts of ¥12,305 million has been disclosed against loans to medical corporations and others, indicating the material financial significance of credit risk associated with the medical business. - FY2019First statedAnnual report
「If the financial condition of a business partner deteriorates in the future, the Group may have no choice but to increase its allowance for doubtful accounts, which could adversely affect its business results and financial condition.」
The company discloses credit risk related to business and investment and financing activities and the possibility of an increase in the allowance for doubtful accounts.